Davey Mitchell Smith

The paper deconvolves HIV-1 mutational signatures across anatomical compartments and identifies APOBEC3-associated mutagenesis as a major contributor, showing donor-specific patterns.

This study examines the cell-type specific effects of opioid use disorder and HIV on the human brain, identifying changes in gene regulation, metabolism, and immune responses across different brain regions.

This study uses GALILEO and ChemPrint to generate novel antiviral compounds targeting the conserved Thumb-1 site, achieving 100% hit rate in vitro against HCV and Coronavirus 229E.

The paper examines early T cell and antibody responses in COVID-19 patients and finds they correlate with reduced SARS-CoV-2 viral RNA in the upper respiratory tract.

This study shows that SARS-CoV-2 mAb treatment shifts memory B cell epitope recognition, affecting their response to vaccination.

This paper models viral resistance emergence in SARS-CoV-2 treated with anti-spike monoclonal antibodies, showing that target cell replenishment mechanisms can explain high viral rebounds.

The paper identifies the RdRp Thumb-1 pocket as a conserved target for broad-spectrum antivirals, validated through structural and biochemical analyses of multiple viruses.

ChemPrint improves drug discovery by enhancing hit rates and chemical novelty through a novel AI framework, achieving higher performance on challenging targets.

The paper identifies a conserved 166-gene host immune signature across viral pandemics, with a 20-gene subset predicting disease severity and guiding therapeutic strategies.

MrHAMER enables accurate long-range viral sequencing, allowing analysis of intra-host evolution and genetic interactions in HIV.

This paper introduces ProACT, a phylogenetic method for prioritizing HIV-positive individuals based on viral sequence branch lengths to improve public health resource allocation.